Innovis further expands its Gx product portfolio in Greece

Gx portfolio acquisition

We are excited to announce our portfolio expansion, through the acquisition of GAP’s established pharmaceutical Gx branded products, following the clearance of the Hellenic Competition Commission (HCC).
The agreement marks an exciting milestone for the evolution of Innovis, further strengthening our commercial footprint in the Greek market, in specialties where we already offer a wide range of therapeutic solutions.
The structure of the agreement ensures the uninterrupted access for the patients to all transferred pharmaceutical products, from now on commercialized by our operational platform!

Linkedin Announcement 
#innovispharma #innovisgrowth #pharmaagreement